Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | PARP1 | P09874 | 1/20 | 0.40 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.40 |
| ▸ | KDM1A | O60341 | 1/20 | 0.39 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.38 |
| ▸ | METAP1 | P53582 | 1/20 | 0.38 |
| ▸ | MALT1 | Q9UDY8 | 1/20 | 0.35 |
| ▸ | BACE1 | P56817 | 4/20 | 0.35 |
| ▸ | TYMS | P04818 | 1/20 | 0.35 |
| ▸ | TDP2 | O95551 | 1/20 | 0.33 |
| ▸ | APP | P05067 | 1/20 | 0.33 |
| ▸ | PNMT | P11086 | 1/20 | 0.33 |
| ▸ | ASIC3 | Q9UHC3 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL447986 | 0.79 | TDP1 (0.51) | TDP1L3MBTL1PARP1PARP10KDM1A | |
| SCHEMBL8778992 | 0.78 | TDP1 (0.39) | TDP1L3MBTL1PARP1PARP10KDM1A | |
| SCHEMBL1706762 | 0.76 | KDM1A (0.53) | TDP1L3MBTL1KDM1ABACE1TDP2 | |
| SCHEMBL6859836 | 0.76 | HTR2A (0.42) | L3MBTL1PARP1PARP10KDM1A | |
| SCHEMBL29804270 | 0.76 | KDM1A (0.53) | TDP1L3MBTL1KDM1ABACE1TDP2 | |
| SCHEMBL17355136 | 0.74 | TDP1 (0.43) | TDP1L3MBTL1KDM1AMETAP1BACE1 | |
| SCHEMBL2223847 | 0.74 | KDM1A (0.43) | PARP1KDM1APDE4BMETAP1BACE1 | |
| SCHEMBL9418940 | 0.70 | TDP1 (0.45) | TDP1L3MBTL1PARP1PARP10KDM1A | |
| SCHEMBL598138 | 0.70 | TDP1 (0.61) | TDP1L3MBTL1PARP1PARP10KDM1A | |
| SCHEMBL29914776 | 0.70 | TDP1 (0.52) | TDP1L3MBTL1PARP1PARP10KDM1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120065195-A1 | COMPOUNDS FOR TREATING NEURODEGENERATIVE DISEASES | ARRAY BIOPHARMA INC. | 2012-03-15 | — | — | US | disclosed |
| WO-2011123674-A1 | COMPOUNDS FOR TREATING NEURODEGENERATIVE DISEASES | ARRAY BIOPHARMA INC. (US) | 2011-10-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120065195-A1 | COMPOUNDS FOR TREATING NEURODEGENERATIVE DISEASES | APP, BACE1, PSEN1 | TDP1 200/4885L3MBTL1 4213/4885PARP1 1287/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.